Teva Pharmaceuticals claims two companies are violating patents on Copaxone, glatiramer acetate for Multiple Sclerosis (MS). The original suit against Momenta Pharmaceuticals and Sandoz now has expanded to include ten patents, three of which run past the expected generic drug entry of 2014…so when generics will appear is now an open question. Copaxone, approved as an orphan drug, is Teva’s flagship product, with sales of over $680 million a year. In addition to being in clinical trials for various combinations, dosage rates, and administration strategies in the mitigation of MS, the drug is now also being studied for macular degeneration and Crohn’s Disease.
Three such opportunities were identified by recruiting firm Smith Hanley Associates earlier this year: One was candidate movement to smaller biopharmas, which the firm said leads to higher base salaries as companies scramble to offset the loss of long-term incentives given by big pharma. Mergers and acquisitions create jobs for candidates willing to relocate, whereas the growth of big data adds positions for in-house data scientists but also results in project outsourcing to vendors that creates new markets and innovations, Smith Hanley added.